Tharimmune (THAR) News Today → Kiss of death from Joe Biden (From Porter & Company) (Ad) Free THAR Stock Alerts $4.75 +0.26 (+5.80%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 29, 2024 | finanznachrichten.deTharimmune, Inc.: Tharimmune to Present at 2024 BIO International ConventionMay 29, 2024 | finance.yahoo.comTharimmune to Present at 2024 BIO International ConventionMay 28, 2024 | marketbeat.comShort Interest in Tharimmune, Inc. (NASDAQ:THAR) Decreases By 83.2%Tharimmune, Inc. (NASDAQ:THAR - Get Free Report) was the recipient of a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 20,000 shares, a decline of 83.2% from the April 30th total of 119,000 shares. Based on an average daily trading volume, of 299,400 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.2% of the company's shares are sold short.May 24, 2024 | investorplace.comWhy Is Tharimmune (THAR) Stock Moving Today?May 24, 2024 | americanbankingnews.comTharimmune (NASDAQ:THAR) Shares Scheduled to Reverse Split on Tuesday, May 28thMay 22, 2024 | msn.comWhy Tharimmune (THAR) Shares Are MovingMay 22, 2024 | finanznachrichten.deTharimmune, Inc.: Tharimmune Announces 1-for-15 Reverse Stock SplitMay 22, 2024 | finance.yahoo.comTharimmune Announces 1-for-15 Reverse Stock SplitMay 9, 2024 | investorplace.comTHAR Stock Earnings: Tharimmune Reported Results for Q4 2023May 2, 2024 | finance.yahoo.comStonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus ManagementApril 24, 2024 | finance.yahoo.comTharimmune, Inc. (THAR)April 18, 2024 | morningstar.comTharimmune Inc THARApril 16, 2024 | investing.comTharimmune forms advisory board to guide drug developmentFebruary 21, 2024 | msn.comTharimmune’s buccal film liver drug demonstrates effectiveness in Phase I trialFebruary 20, 2024 | msn.comTharimmune's Oral 'Under The Cheek' Candidate At Par With FDA-Approved Injectable With Potential For Chronic Liver DiseaseFebruary 20, 2024 | finanznachrichten.deTharimmune, Inc.: Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic CandidateFebruary 20, 2024 | finance.yahoo.comTharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic CandidateFebruary 9, 2024 | msn.comTharimmune’s Active Common Stock Shares UpdateFebruary 5, 2024 | finance.yahoo.comTharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary CholangitisJanuary 29, 2024 | finanznachrichten.deTharimmune, Inc.: Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business UpdateDecember 11, 2023 | finance.yahoo.comTharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease PatientsNovember 30, 2023 | finance.yahoo.comTharimmune, Inc. Announces Closing of $11 Million Public OfferingNovember 30, 2023 | msn.comWhy Tharimmune Stock (THAR) Is Down 70% TodayNovember 29, 2023 | msn.comWhy Is Liver Disease Focused Tharimmune Stock Trading Higher Today?November 29, 2023 | marketwatch.comTharimmune Shares Hit 52-Week Low After Public Offering PricesNovember 29, 2023 | msn.comTharimmune announces pricing of $10 million public offeringNovember 29, 2023 | markets.businessinsider.comCrude Oil Surges 2%; Tharimmune Shares PlummetNovember 29, 2023 | finance.yahoo.comTharimmune, Inc. Announces Pricing of $10 Million Public OfferingNovember 28, 2023 | investorplace.comWhy Is Tharimmune (THAR) Stock Down 70% Today?November 21, 2023 | marketbeat.comTrading was temporarily halted for "THAR" at 07:11 PM with a stated reason of "News pending."November 7, 2023 | investorplace.comWhy Is Tharimmune (THAR) Stock Up 113% Today? Get Tharimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for THAR and its competitors with MarketBeat's FREE daily newsletter. Email Address This military-backed stock “owns” AI market (Ad)The AI boom is just getting started. And the real wealth has still to be made… You must read this new presentation from Porter Stansberry. THAR Media Mentions By Week THAR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. THAR News Sentiment▼0.960.76▲Average Medical News Sentiment THAR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. THAR Articles This Week▼51▲THAR Articles Average Week Get Tharimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for THAR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: XBiotech News Today Pyxis Oncology News Today Conduit Pharmaceuticals News Today Eliem Therapeutics News Today Werewolf Therapeutics News Today Aldeyra Therapeutics News Today Design Therapeutics News Today 2seventy bio News Today Renovaro News Today Akebia Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:THAR) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsElon to Transform U.S. Economy? Porter & CompanyBiden replacement revealed?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tharimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
